Greylin Investment Management’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $219K | Hold |
2,020
| – | – | 0.04% | 77 |
|
|
2024
Q1 | $267K | Sell |
2,020
-9
| -0.4% | -$1.12K | 0.04% | 69 |
|
|
2023
Q4 | $247K | Sell |
2,029
-66
| -3% | -$7.36K | 0.04% | 70 |
|
|
2023
Q3 | $235K | Sell |
2,095
-25
| -1% | -$3.17K | 0.04% | 67 |
|
|
2023
Q2 | $309K | Hold |
2,120
| – | – | 0.06% | 58 |
|
|
2023
Q1 | $274K | Hold |
2,120
| – | – | 0.05% | 65 |
|
|
2022
Q4 | $270K | Sell |
2,120
-50
| -2% | -$5.8K | 0.05% | 61 |
|
|
2022
Q3 | $227K | Sell |
2,170
-125
| -5% | -$13.7K | 0.05% | 65 |
|
|
2022
Q2 | $241K | Sell |
2,295
-430
| -16% | -$51K | 0.05% | 66 |
|
|
2022
Q1 | $349K | Sell |
2,725
-442
| -14% | -$53.3K | 0.06% | 70 |
|
|
2021
Q4 | $391K | Hold |
3,167
| – | – | 0.07% | 73 |
|
|
2021
Q3 | $450K | Sell |
3,167
-26
| -0.8% | -$3.83K | 0.09% | 66 |
|
|
2021
Q2 | $499K | Sell |
3,193
-77
| -2% | -$12.5K | 0.1% | 67 |
|
|
2021
Q1 | $508K | Sell |
3,270
-52
| -2% | -$8.05K | 0.11% | 67 |
|
|
2020
Q4 | $497K | Sell |
3,322
-51
| -2% | -$7.2K | 0.12% | 60 |
|
|
2020
Q3 | $446K | Sell |
3,373
-309
| -8% | -$40.4K | 0.12% | 61 |
|
|
2020
Q2 | $427K | Hold |
3,682
| – | – | 0.12% | 61 |
|
|
2020
Q1 | $361K | Sell |
3,682
-335
| -8% | -$43.9K | 0.11% | 56 |
|
|
2019
Q4 | $584K | Sell |
4,017
-901
| -18% | -$124K | 0.13% | 47 |
|
|
2019
Q3 | $655K | Sell |
4,918
-335
| -6% | -$43.3K | 0.16% | 49 |
|
|
2019
Q2 | $600K | Sell |
5,253
-26
| -0.5% | -$3.04K | 0.13% | 50 |
|
|
2019
Q1 | $654K | Sell |
5,279
-103
| -2% | -$11.7K | 0.15% | 53 |
|
|
2018
Q4 | $542K | Sell |
5,382
-26
| -0.5% | -$2.92K | 0.13% | 53 |
|
|
2018
Q3 | $690K | Hold |
5,408
| – | – | 0.15% | 48 |
|
|
2018
Q2 | $585K | Sell |
5,408
-93
| -2% | -$10.1K | 0.13% | 55 |
|
|
2018
Q1 | $582K | Buy |
5,501
+68
| +1% | +$7.9K | 0.13% | 52 |
|
|
2017
Q4 | $637K | Hold |
5,433
| – | – | 0.14% | 50 |
|
|
2017
Q3 | $618K | Hold |
5,433
| – | – | 0.14% | 47 |
|
|
2017
Q2 | $677K | Hold |
5,433
| – | – | 0.16% | 47 |
|
|
2017
Q1 | $644K | Sell |
5,433
-52
| -0.9% | -$5.89K | 0.15% | 51 |
|
|
2016
Q4 | $550K | Hold |
5,485
| – | – | 0.13% | 51 |
|
|
2016
Q3 | $692K | Sell |
5,485
-221
| -4% | -$27.3K | 0.17% | 46 |
|
|
2016
Q2 | $667K | Sell |
5,706
-927
| -14% | -$105K | 0.17% | 46 |
|
|
2016
Q1 | $687K | Sell |
6,633
-206
| -3% | -$19.9K | 0.18% | 40 |
|
|
2015
Q4 | $681K | Buy |
+6,839
| New | +$669K | 0.18% | 38 |
|
|
2015
Q2 | – | Sell |
-6,736
| Closed | -$742K | – | 62 |
|
|
2015
Q1 | $742K | Sell |
6,736
-206
| -3% | -$23.5K | 0.18% | 39 |
|
|
2014
Q4 | $764K | Sell |
6,942
-206
| -3% | -$21.7K | 0.18% | 38 |
|
|
2014
Q3 | $698K | Sell |
7,148
-309
| -4% | -$30.4K | 0.17% | 40 |
|
|
2014
Q2 | $752K | Sell |
7,457
-206
| -3% | -$20.1K | 0.18% | 38 |
|
|
2014
Q1 | $704K | Sell |
7,663
-77
| -1% | -$7.1K | 0.17% | 44 |
|
|
2013
Q4 | $700K | Buy |
+7,740
| New | +$670K | 0.17% | 44 |
|
Other funds holding ZBH
Greylin Investment Management's ZBH Position: Q2 2024 in Review
Greylin Investment Management held its Zimmer Biomet (ZBH) position steady in Q2 2024 at 2,020 shares worth $219K. The position accounts for 0.04% of the portfolio, ranked #77.
Greylin Investment Management first reported a position in ZBH in Q4 2013 and has held it in 41 quarters since. The position peaked at $764K in Q4 2014. 1,008 funds tracked by Wall St. Rank hold ZBH as of Q2 2024.
- Greylin Investment Management held 2,020 shares of Zimmer Biomet worth $219K as of Q2 2024.
- Greylin Investment Management left its Zimmer Biomet share count unchanged in Q2 2024.
- Zimmer Biomet made up 0.04% of Greylin Investment Management's portfolio in Q2 2024, its #77 holding.
- Greylin Investment Management first reported a position in Zimmer Biomet in Q4 2013 and has held it in 41 quarters since.
- Greylin Investment Management's Zimmer Biomet position peaked at $764K in Q4 2014.
- 1,008 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2024.
Based on Greylin Investment Management's 13F filing for Q2 2024, filed 19 Jul 2024.